These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37434386)

  • 21. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
    Kawano Y; Takahashi W; Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S
    Cancer Sci; 2016 Jul; 107(7):1013-7. PubMed ID: 27089226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
    Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
    Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
    Cetin B; Afsar B; Deger SM; Gonul II; Gumusay O; Ozet A; Benekli M; Coskun U; Buyukberber S
    Int Urol Nephrol; 2014 Jun; 46(6):1081-7. PubMed ID: 24307427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Xu Y; Zhang Y; Wang X; Kang J; Liu X
    BMC Cancer; 2019 Feb; 19(1):168. PubMed ID: 30795756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
    Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM; Harris WB; Kucuk O; Master VA; Bilen MA
    Cancer Treat Res Commun; 2021; 28():100393. PubMed ID: 34029879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
    Chrom P; Zolnierek J; Bodnar L; Stec R; Szczylik C
    Int J Clin Oncol; 2019 May; 24(5):526-532. PubMed ID: 30604160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
    Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
    Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma.
    Drljevic-Nielsen A; Donskov F; Mains JR; Andersen MB; Thorup K; Thygesen J; Rasmussen F
    AJR Am J Roentgenol; 2022 May; 218(5):867-876. PubMed ID: 34910540
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma.
    Ikeda T; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
    Target Oncol; 2018 Jun; 13(3):379-387. PubMed ID: 29785576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab.
    Ekinci F; Erdogan AP; Yildirim S; Bulut G; Yilmaz C; Barutca S
    J Coll Physicians Surg Pak; 2022 Oct; 32(10):1288-1294. PubMed ID: 36205273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
    Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients.
    Kankkunen E; Penttilä P; Peltola K; Bono P
    Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
    Mazzaschi G; Lazzarin A; Santoni M; Trentini F; Giorgi U; Brighi N; Tommasi C; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; Silini EM; Rescigno P; Rebuzzi SE; Fornarini G; Quaini F; Giudice GC; Banna GL; Buti S
    Front Biosci (Elite Ed); 2023 Jul; 15(3):20. PubMed ID: 37743233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.
    Soerensen AV; Donskov F; Hermann GG; Jensen NV; Petersen A; Spliid H; Sandin R; Fode K; Geertsen PF
    Eur J Cancer; 2014 Feb; 50(3):553-62. PubMed ID: 24215846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study.
    Choi J; Bang S; Suh J; Choi CI; Song W; Yuk HD; Lee CH; Kang M; Choo SH; Kim JK; Lee HH; Jo JK; Hwang EC; Jeong CW; Ko YH; Park JY; Song C; Seo SI; Chung J; Kwak C; Hong SH
    Sci Rep; 2024 Feb; 14(1):4740. PubMed ID: 38413653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
    Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
    BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Yasuda Y; Saito K; Yuasa T; Uehara S; Kawamura N; Yokoyama M; Ishioka J; Matsuoka Y; Yamamoto S; Okuno T; Yonese J; Kihara K; Fujii Y
    Int J Clin Oncol; 2017 Dec; 22(6):1081-1086. PubMed ID: 28733795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.